Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial

Peer Review reports

Original Submission
25 Mar 2022	Submitted	Original manuscript
25 Jul 2022	Reviewed	Reviewer Report
27 Aug 2022	Reviewed	Reviewer Report
1 Nov 2022	Author responded	Author comments - Patrick Schöffski
14 Nov 2022	Author responded	Author comments - Patrick Schöffski
Resubmission - Version 2
1 Nov 2022	Submitted	Manuscript version 2
26 Nov 2022	Reviewed	Reviewer Report
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
28 Nov 2022	Editorially accepted
13 Dec 2022	Article published	10.1186/s12885-022-10379-9

Back to article page